On June 24th, 2019 Dmytro Aleshko, partner at Legal Alliance Company and legal advisor of SAFEMed project, participated in the meeting of members of the EBA Healthcare Committee where market participants and the Ministry of Health of Ukraine discussed further steps of the reform due to introduction of reference pricing to some medicines procured for budget funds.
Let us remind you that from July 1st, 2019 in accordance with Resolution of the Cabinet of Ministers of Ukraine No. 426 as of April 2019 state regulation of prices for some medicines procured for budget funds and included to the list of medicines made by the Ministry of Health is introduced by setting maximum ex-factory prices for them based on prices for medicines registered in Poland, Slovakia, Czech Republic, Latvia and Hungary.
“At the meeting some manufacturers expressed their worries that they will not be able to supply medicines at the new prices set by the Ministry of Health. In this matter it is extremely difficult to ensure constant monitoring of availability of the necessary medicines at medical facilities to guarantee continuous treatment to patients”, emphasized Dmytro Aleshko.
***
Legal Alliance Company is legal advisor of USAID project “Safe, Affordable and Effective Medicines for Ukrainians” (SAFEMed), which is aimed at reinforcing the system of medicines provision to the population due to increase in its transparency and economical feasibility of medicines.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.
